otelixizumab 治疗新发1型糖尿病的剂量探索安全性研究
这项随机、单盲、安慰剂对照、为期24个月的多中心研究,在比利时5个中心纳入16–27岁、诊断为1型糖尿病不足32天的患者,评估抗CD3单克隆抗体otelixizumab四个累积剂量(9、18、27、36 mg)的安全性、耐受性、β细胞功能与免疫效应。otelixizumab 9 mg组混合餐耐量试验C肽AUC较基线升高持续至18个月,与安慰剂差异0.39(95%CI 0.06, 0.72;p=0.023);18 mg与27 mg未见β细胞功能保护。27 mg组因预设EBV再激活停止标准而终止给药,EBV再激活及临床表现呈剂量依赖且短暂。
要点
- otelixizumab 9 mg与安慰剂相比C肽AUC差异0.39(95%CI 0.06, 0.72;p=0.023),维持至18个月。
- 18 mg与27 mg剂量未观察到β细胞功能保护作用。
- 27 mg组达到预设EBV再激活停止标准,EBV再激活呈剂量依赖且短暂。
核心结论
- otelixizumab 9 mg观察到代谢应答,而高于18 mg的剂量增加 unwanted 临床EBV再激活风险。
- otelixizumab可暂时损害免疫能力使EBV再激活,但该效应呈剂量依赖且短暂,EBV特异性T细胞快速出现并最终控制再激活。
研究设计与样本
- 随机、单盲、安慰剂对照、24个月研究,比利时5个中心经比利时糖尿病登记处开展。
- 纳入16–27岁、诊断1型糖尿病不足32天的参与者,计划n=40,随机接受安慰剂或otelixizumab四个累积静脉剂量(9、18、27或36 mg,6天内给药)。
- 随机化由中央计算机系统完成,仅参与者和床旁研究人员对治疗设盲。
- 共同主要终点为不良事件发生率、EBV再激活率以及实验室指标和生命体征。
主要发现
- 不良事件频率和严重程度呈剂量依赖;所有接受otelixizumab的参与者在给药期间至少发生一次与细胞因子释放综合征相关的不良事件。
- EBV再激活:9 mg组2/9、18 mg组4/8、27 mg组5/7;临床表现:9 mg组0/9、18 mg组1/8、27 mg组3/7,均快速、剂量依赖且短暂。
- EBV再激活伴随生产性T细胞克隆性增加,随后随时间减弱。
- otelixizumab 9 mg组混合餐耐量试验C肽加权平均AUC0-120 min较基线升高持续至18个月,与安慰剂差异0.39(95%CI 0.06, 0.72;p=0.023)。
- 18 mg与27 mg剂量未观察到β细胞功能保护。
关键数值与推荐
- otelixizumab累积静脉剂量分组为9、18、27或36 mg,6天内给药。
- 27 mg组因达到预设EBV再激活停止标准而停止给药,36 mg组n=0。
- 9 mg组C肽加权平均AUC0-120 min与安慰剂差异0.39(95%CI 0.06, 0.72;p=0.023)。
临床怎么用
- 新发1型糖尿病中otelixizumab的获益与风险呈剂量相关,9 mg与代谢应答相关而18 mg及以上未见β细胞保护且EBV再激活风险升高。
- 用药期间需监测细胞因子释放综合征相关不良事件及EBV再激活。
- EBV再激活虽可暂时损害免疫能力,但呈剂量依赖和短暂性,需关注EBV特异性T细胞出现与长期控制。
局限性
- 样本量小,28例纳入分析,各剂量组例数有限。
- 36 mg组n=0,最高剂量未实际评估。
- 单盲设计,仅参与者和床旁研究人员设盲。
- 研究在比利时5个中心开展,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Numerous clinical studies have investigated the anti-CD3ɛ monoclonal antibody otelixizumab in individuals with type 1 diabetes, but limited progress has been made in identifying the optimal clinical dose with acceptable tolerability and safety. The aim of this study was to evaluate the association between dose-response, safety and tolerability, beta cell function preservation and the immunological effects of otelixizumab in new-onset type 1 diabetes. METHODS: In this randomised, single-blind, placebo-controlled, 24 month study, conducted in five centres in Belgium via the Belgian Diabetes Registry, participants (16-27 years old, <32 days from diagnosis of type 1 diabetes) were scheduled to receive placebo or otelixizumab in one of four dose cohorts (cumulative i.v. dose 9, 18, 27 or 36 mg over 6 days; planned n = 40). Randomisation to treatment was by a central computer system; only participants and bedside study personnel were blinded to study treatment. The co-primary endpoints were the incidence of adverse events, the rate of Epstein-Barr virus (EBV) reactivation, and laboratory measures and vital signs. A mixed-meal tolerance test was used to assess beta cell function; exploratory biomarkers were used to measure T cell responses. RESULTS: Thirty participants were randomised/28 were analysed (placebo, n = 6/5; otelixizumab 9 mg, n = 9/8; otelixizumab 18 mg, n = 8/8; otelixizumab 27 mg, n = 7/7; otelixizumab 36 mg, n = 0). Dosing was stopped at otelixizumab 27 mg as the predefined EBV reactivation stopping criteria were met. Adverse event frequency and severity were dose dependent; all participants on otelixizumab experienced at least one adverse event related to cytokine release syndrome during the dosing period. EBV reactivation (otelixizumab 9 mg, n = 2/9; 18 mg, n = 4/8: 27 mg, n = 5/7) and clinical manifestations (otelixizumab 9 mg, n = 0/9; 18 mg, n = 1/8; 27 mg, n = 3/7) were rapid, dose dependent and transient, and were associated with increased productive T cell clonality that diminished over time. Change from baseline mixed-meal tolerance test C-peptide weighted mean AUC0-120 min following otelixizumab 9 mg was above baseline for up to 18 months (difference from placebo 0.39 [95% CI 0.06, 0.72]; p = 0.023); no beta cell function preservation was observed at otelixizumab 18 and 27 mg. CONCLUSIONS/INTERPRETATION: A metabolic response was observed with otelixizumab 9 mg, while doses higher than 18 mg increased the risk of unwanted clinical EBV reactivation. Although otelixizumab can temporarily compromise immunocompetence, allowing EBV to reactivate, the effect is dose dependent and transient, as evidenced by a rapid emergence of EBV-specific T cells preceding long-term control over EBV reactivation. TRIAL REGISTRATION: ClinicalTrials.gov NCT02000817. FUNDING: The study was funded by GlaxoSmithKline. Graphical abstract.
引用
- Keymeulen B, van Maurik A, Inman D, et al. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes. Diabetologia. 2020. PMID: 33145642. doi:10.1007/s00125-020-05317-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。